Xbrane Gets US Setback For Ranibizumab Filing

BLA For Biosimilar Lucentis Rival Withdrawn As FDA Asks For More Information

 
• By David Wallace
  
Sign outside of FDA's headquarters in White Oak, MD
The FDA has requested more information on the Xlucane filing • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products